Results 141 to 150 of about 27,201 (202)

Anti-Human Epidermal Growth Factor Receptor 2 therapies in metastatic colorectal cancer: a systematic review and meta-analysis. [PDF]

Oncologist
Rota S, Di Nardo P, Zottarelli E, Giudici F, Vida R, Zilli M, de Scordilli M, Foltran L, Fumagalli A, Guardascione M, Ongaro E, Puglisi F.   +11 more
europepmc   +1 more source

Case Report: response of HER2-positive ductal carcinoma <i>in situ</i> to osimertinib with supporting <i>in vitro</i> evidence. [PDF]

Front Oncol
Baba S, Koketsu M, Kuroda H, Suzuki M, Nishihara H, Kato Y, Kawami H, Harada O.   +7 more
europepmc   +1 more source

Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors. [PDF]

Int J Mol Sci
Bandala C, López-Méndez JA, Díaz-Rivera MRJ, Carro-Rodríguez J, Bello M.   +4 more
europepmc   +1 more source

A <i>CFH</i>- and <i>SPINT2</i>-based prognostic signature for cholangiocarcinoma. [PDF]

J Gastrointest Oncol
Chen S, Ma W, Li B, Zhang J, Xie W.
europepmc   +1 more source

[Retracted] Antitumor activity of NRC‑AN‑019 in a pre‑clinical breast cancer model. [PDF]

Int J Oncol
Gondi CS, Gorantla B, Rao AKSB, Amala K, Naidu MUR, Jogi KV, Ramana GV, Myneni PC, Junnarkar A, Rao JS.   +9 more
europepmc   +1 more source

Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]. [PDF]

EClinicalMedicine
De Santis MC, Campbell C, Samy F, De Rose F, Meduri B, Lambertini M, Sotiriou C, Carnevale MG, Ferro A, Saura C, Choudhury A, Giandini C, Verderio P, Chumsri S, Appierto V, Piccart M, Pruneri G, Colciago RR, de Azambuja E, Di Cosimo S.   +19 more
europepmc   +1 more source

Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database. [PDF]

J Pharm Policy Pract
Cerbito E, Diab MI, Alhoshani A, Maayah ZH.   +3 more
europepmc   +1 more source

Kinase Plasticity with Vandetanib Treatment Enhances Sensitivity to Tamoxifen in Estrogen Receptor Positive Breast Cancer. [PDF]

Mol Cancer Ther
Whitman AA, Kakati RT, Haase S, Thai CH, Tripathi SK, Szenasi AT, Brunk EC, Okumu DO, East MP, Molina SG, Beltran AS, Raab JR, Carey LA, Perou CM, Johnson GL, Spanheimer PM.   +15 more
europepmc   +1 more source